Copeptin and cardiovascular disease: A review of a novel neurohormone

YALTA A. K., YALTA T. D., SİVRİ N., Yetkin E.

International Journal of Cardiology, vol.167, no.5, pp.1750-1759, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 167 Issue: 5
  • Publication Date: 2013
  • Doi Number: 10.1016/j.ijcard.2012.12.039
  • Journal Name: International Journal of Cardiology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1750-1759
  • Keywords: Arginine vasopressin, Cardiovascular disease, Clinical implication, Copeptin
  • Trakya University Affiliated: Yes

Abstract

Neurohormones (NHs) in the cascade of the arginine vasopressin (AVP) system have drawn particular attention in the recent years. Copeptin, the C-terminal portion of provasopressin, is a novel NH of the AVP system, and is known to be co-released with AVP from hypothalamus (neurohypophysis). As a surrogate marker of the AVP system, copeptin has gradually replaced AVP in several clinical studies largely due to its structural and methodological advantages. Copeptin has been regarded as a marker of non-specific stress response, and has also been suggested to have clinical implications in a variety of non-cardiovascular (pneumonia, sepsis, etc.) and cardiovascular conditions (heart failure and acute coronary syndromes (ACSs, etc.)). However, current data on relation of copeptin with other cardiovascular conditions (arrhythmias, etc.) are still insufficient. The present review primarily focuses on general features of copeptin, its general clinical implications, and specifically aims to cover its potential clinical value in a variety of cardiovascular conditions. © 2012 Elsevier Ireland Ltd.